Biofrontera Inc. Operating Expenses
Biofrontera Inc. (BFRI) reported Operating Expenses of $12.53 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-13
- Biofrontera Inc. operating expenses for the quarter ending 2026-06-30 was $12.53M, a 11.21% decline year-over-year.
- Biofrontera Inc. operating expenses for the quarter ending 2026-03-31 was $14.40M, a 9.66% increase year-over-year.
- Biofrontera Inc. operating expenses for the quarter ending 2025-06-30 was $14.11M, a 9.29% increase year-over-year.
- Biofrontera Inc. operating expenses for the quarter ending 2025-03-31 was $13.13M, a 1.82% decline year-over-year.
- Biofrontera Inc. operating expenses for fiscal 2025 was $53.05M, a 2.71% decline from fiscal 2024.
- Biofrontera Inc. operating expenses for fiscal 2024 was $54.53M, a 3.91% decline from fiscal 2023.
- Biofrontera Inc. operating expenses for fiscal 2023 was $56.75M, a 20.09% increase from fiscal 2022.
- Biofrontera Inc. operating expenses for fiscal 2022 was $47.26M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.53M 10-Q · filed 2026-08-13 | $26.93M 10-Q · filed 2026-08-13 | ||
| 2026-03-31 | $14.40M 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | $53.05M 10-K · filed 2026-03-19 | |||
| 2025-06-30 | $14.11M 10-Q · filed 2026-08-13 | $27.25M 10-Q · filed 2026-08-13 | $41.52M derived: sum of 3 quarters · filed 2026-08-13 | $55.49M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $13.13M 10-Q · filed 2026-05-14 | $27.41M derived: sum of 2 quarters · filed 2026-05-14 | $41.38M derived: sum of 3 quarters · filed 2026-05-14 | $54.29M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $14.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $28.24M derived: sum of 2 quarters · filed 2026-03-19 | $41.15M derived: sum of 3 quarters · filed 2026-03-19 | $54.53M 10-K · filed 2026-03-19 |
| 2024-09-30 | $13.97M 10-Q · filed 2024-11-14 | $26.88M derived: sum of 2 quarters · filed 2024-11-14 | $40.26M 10-Q · filed 2024-11-14 | $54.72M derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-06-30 | $12.91M 10-Q · filed 2024-08-14 | $26.29M 10-Q · filed 2024-08-14 | $40.75M derived: sum of 3 quarters · filed 2024-08-14 | $54.27M derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-03-31 | $13.38M 10-Q · filed 2024-05-15 | $27.84M derived: sum of 2 quarters · filed 2024-05-15 | $41.36M derived: sum of 3 quarters · filed 2024-11-14 | $55.90M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-12-31 | $14.46M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $27.98M derived: sum of 2 quarters · filed 2024-11-14 | $42.52M derived: sum of 3 quarters · filed 2024-11-14 | $56.75M 10-K · filed 2024-03-15 |
| 2023-09-30 | $13.52M 10-Q · filed 2024-11-14 | $28.06M derived: sum of 2 quarters · filed 2024-11-14 | $42.29M 10-Q · filed 2024-11-14 | $58.05M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $14.55M 10-Q · filed 2024-08-14 | $28.77M 10-Q · filed 2024-08-14 | $44.54M derived: sum of 3 quarters · filed 2024-08-14 | $52.50M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $14.22M 10-Q · filed 2024-05-15 | $29.99M derived: sum of 2 quarters · filed 2024-05-15 | $37.95M derived: sum of 3 quarters · filed 2024-05-15 | $48.62M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $15.76M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $23.73M derived: sum of 2 quarters · filed 2024-03-15 | $34.39M derived: sum of 3 quarters · filed 2024-03-15 | $47.26M 10-K · filed 2024-03-15 |
| 2022-09-30 | $7.96M 10-Q · filed 2023-11-09 | $18.63M derived: sum of 2 quarters · filed 2023-11-09 | $31.49M 10-Q · filed 2023-11-09 | $42.54M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $10.67M 10-Q · filed 2023-08-11 | $23.53M 10-Q · filed 2023-08-11 | $34.58M derived: sum of 3 quarters · filed 2023-10-03 | $55.02M derived: sum of 4 quarters · filed 2023-10-03 |
| 2022-03-31 | $12.86M 10-Q · filed 2023-05-12 | $23.91M derived: sum of 2 quarters · filed 2023-10-03 | $44.35M derived: sum of 3 quarters · filed 2023-10-03 | $53.89M derived: sum of 4 quarters · filed 2023-10-03 |
| 2021-12-31 | $11.05M derived: 8-K 12 month − 10-Q 9 month · filed 2023-10-03 | $31.49M derived: sum of 2 quarters · filed 2023-10-03 | $41.03M derived: sum of 3 quarters · filed 2023-10-03 | $49.30M 8-K · filed 2023-10-03 |
| 2021-09-30 | $20.44M 10-Q · filed 2022-11-14 | $29.98M derived: sum of 2 quarters · filed 2022-11-14 | $38.25M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $9.54M 10-Q · filed 2022-08-12 | $17.81M 10-Q · filed 2022-08-12 | ||
| 2021-03-31 | $8.27M 10-Q · filed 2022-05-13 | |||
| 2020-12-31 | $28.45M 10-K · filed 2022-04-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B |